MedPath

A Multicenter Retrospective Study on the Clinical Course of Smoldering Multiple Myeloma(SMM) Patients in Asia

Not Applicable
Conditions
Smoldering multiple myeloma
Registration Number
JPRN-UMIN000019059
Lead Sponsor
Sapporo Medical University School of MedicineDepartment Gastroenterology, Rheumatology and Clinical Immunol
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

symptomatic multiple myeloma

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
High-risk factors in Asian SMM patients (The high-risk factor or the combination of high-risk factors that 60% of SMM patients progress for symptomatic myeloma within two years)
Secondary Outcome Measures
NameTimeMethod
1.Periods from SMM to symptomatic myeloma 2.Progress rate to symptomatic myeloma at two and five years after the diagnosis of SMM 3.Five-year overall survival rate from the diagnosis of SMM 4.Overall survival of SMM
© Copyright 2025. All Rights Reserved by MedPath